Stimulation of macrophage TNFα production by orthopaedic wear particles requires activation of the ERK1/2/Egr-1 and NF-κB pathways but is independent of p38 and JNK

Journal of Cellular Physiology

Volumn 217, Issue 3, 2008, Pages 652-666

  Beidelschies, Michelle A ^a   Huang, Honglian ^b   Mcmullen, Megan R ^b   Smith, Matthew V ^b   Islam, Andrew S ^a   Goldberg, Victor M ^a   Chen, Xin ^a   Nagy, Laura E ^b   Greenfield, Edward M ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 (2 AMINO 4 PYRIMIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CYTOKINE; EARLY GROWTH RESPONSE FACTOR 1; ENDOTOXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SB 202747; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TITANIUM; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; U 0124; UNCLASSIFIED DRUG; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN C JUN;

ANIMAL CELL; ARTICLE; CELL ADHESION; CELL DIFFERENTIATION; CONTROLLED STUDY; IMMUNOBLOTTING; MACROPHAGE ACTIVATION; MALE; MECHANICAL STRESS; MOUSE; NONHUMAN; ORTHOPEDIC EQUIPMENT; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTHESIS LOOSENING; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL LINE; DRUG EFFECT; ENZYME ACTIVATION; MACROPHAGE; METABOLISM; PROSTHESES AND ORTHOSES; SOLUBILITY; UPREGULATION;

ANIMALS; CELL ADHESION; CELL LINE; EARLY GROWTH RESPONSE PROTEIN 1; ENDOTOXINS; ENZYME ACTIVATION; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROSTHESES AND IMPLANTS; PROTO-ONCOGENE PROTEINS C-JUN; SOLUBILITY; TITANIUM; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 54049120274     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21539     Document Type: Article

References (88)

1. Abbas S, Clohisy JC, Abu-Amer Y. 2003. Mitogen-activated protein (MAP) kinases mediate PMMA-induction of osteoclasts. J Orthop Res 21:1041-1048.
2. Akisue T, Bauer TW, Farver CF, Mochida Y. 2002. The effect of particle wear debris on NFkappaB activation and pro-inflammatory cytokine release in differentiated THP-1 cells. J Biomed Mater Res 259:507-515.
3. Anderson P. 2008. Post-transcriptional control of cytokine production. Nat Immunol 9:353-359.
4. Angel P, Hattori K, Smeal T, Karin M. 1988. The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell 55:875-885.
5. Anonymous. 2003. Orthopaedic Device Forum Meeting Summation Report.
6. Baeuerle P, Baltimore D. 1996. NF-kappa B: Ten years after. Cell 87:13-20.
7. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P. 2007. The selectivity of protein kinase inhibitors: A further update. Biochem J 408:297-315.
8. Baldassare J, Bi Y, Bellone C. 1999. The role of p38 mitogen-activated protein kinase in IL-1beta transcription. J Immunol 162:5367-5373.
9. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW. 2001. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98:13681-13686.
10. Bi Y, Seabold JM, Kaar SC, Ragab AA, Goldberg VM, Anderson JM, Greenfield EM. 2001a. Adherent endotoxin on orthopaedic wear particles stimulates cytokine production and osteoclast differentiation. J Bone Miner Res 16:2082-2091.
11. Bi Y, VanDeMotter RR, Ragab AA, Goldberg VM, Anderson JM, Greenfield EM. 2001b. Titanium particles stimulate bone resorption by inducing differentiation of murine osteoclasts. J Bone Joint Surg Am 83A:501-508.
12. Blaine TA, Rosier RN, Puzas JE, Looney RJ, Reynolds PR, Reynolds SD, O'Keefe RJ. 1996. Increased levels of tumor necrosis factor-alpha and interleukin-6 protein and messenger RNA in human peripheral blood monocytes due to titanium particles. J Bone Joint Surg Am 78A:1181-1192.
13. Briant L, Robert-Hebmann V, Sivan V, Brunet A, Pouyssegur J, Devaux C. 1998. Involvement of extracellular signal-regulated kinase module in HIV-mediated CD4 signals controlling activation of nuclear factor-kappaB and AP-1 transcription factors. J Immunol 160:1875-1885.
14. Chen X, Dai JC, Orellana SA, Greenfield EM. 2005. Endogenous protein kinase inhibitorg terminates immediate-early gene expression induced by cAMP-dependent protein kinase (PKA) signaling: Termination depends on PKA inactivation rather than PKA export from the nucleus. J Biol Chem 280:2700-2707.
15. Childs L, Goater J, O'Keefe R, Schwarz E. 2001. Effect of anti-tumor necrosis factor-alpha gene therapy on wear debris-induced osteolysis. J Bone Joint Surg Am 83A:1789-1797.
16. Clohisy D, Bar-Shavit Z, Chappel J, Teitelbaum S. 1987. 1,25-Dihydroxyvitamin D3 modulates bone marrow macrophage precursor proliferation and differentiation. Upregulation of the mannose receptor. J Biol Chem 262:15922-15929.
17. Clohisy JC, Teitelbaum S, Chen S, Erdmann JM, Abu-Amer Y. 2002. Tumor necrosis factor - A mediates polymethylmethacrylate particle-induced NF-kB activation in osteoclast precursor cells. J Orthop Res 20:174-181.
18. Clohisy JC, Hirayama T, Frazier E, Han SK, Abu-Amer Y. 2004. NF-kB signaling blockade abolishes implant particle-induced osteoclastogenesis. J Orthop Res 22:13-20.
19. Cooperstock MS, Tucker RP, Baublis JV. 1975. Possible pathogenic role of endotoxin in Reye's Syndrome. Lancet 1:1272-1274.
20. Covert MW, Leung TH, Gaston JE, Baltimore D. 2005. Achieving stability of lipopolysaccharide-induced NF-kappaB activation. Science 309:1854-1857.
21. Dai JC, He P, Chen X, Greenfield EM. 2006. TNFa and PTH utilize distinct mechanisms to induce IL-6 and RANKL expression with markedly different kinetics. Bone 38:509-520.
22. David JP, Sabapathy K, Hoffmann O, Idarraga MH, Wagner EF. 2002. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci 115:4317-4325.
23. Davies SP, Reddy H, Caivano M, Cohen P. 2000. Specificity andmechanism of action of some commonly used protein kinase inhibitors. Biochem J 351:95-105.
24. Deleault KM, Skinner SJ, Brooks SA. 2008. Tristetraprolin regulates TNF TNF-alpha mRNA stability via a proteasome dependent mechanism involving the combined action of the ERK and p38 pathways. Mol Immunol 45:13-24.
25. Dobson K, Reading L, Haberey M, Marine X, Scutt A. 1999. Centrifugal isolation of bone marrow from bone: An improved method for the recovery and quantitation of bone marrow osteoprogenitor cells from rat tibiae and femurae. Calcif Tissue Int 65:411-413.
26. English JM, Cobb MH. 2002. Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 23:40-45.
27. Fong Y, Tracey K, Moldawer L, Hesse D, Manogue K, Kenney J, Lee A, Kuo G, Allison A, Lowry S, Cerami A. 1989. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med 170:1627-1633.
28. Franzoso G, Carlson L, Xing L, Poljak L, Shores E, Brown K, Leonardi A, Tran T, Boyce B, Siebenlist U. 1997. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 11:3482-3496.
29. Ghoda L, Lin X, Greene WC. 1997. The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IkappaBalpha and stimulates its degradation in vitro. J Biol Chem 272:21281-21288.
30. Greenfield EM, Bi Y, Ragab AA, Goldberg VM, VanDeMotter RR. 2002. The role of osteoclast differentiation in aseptic loosening. J Orthop Res 20:1-8.
31. Greenfield EM, Bi Y, Ragab AA, Goldberg VM, Nalepka JL, Seabold JM. 2005. Does endotoxin contribute to aseptic loosening of orthopaedic implants? J Biomed Mater Res B Appl Biomater 72B:179-185.
32. Guha M, O'Connell MA, Pawlinski R, Hollis A, McGovern P, Yan SF, Stern D, Mackman N. 2001. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor-alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood 98:1429-1439.
33. Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, Firestein GS. 2001. c-JunN-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 108:73-81.
34. Hauschildt S, Brabetz W, Schromm AB, Hamann L, Zabel P, Rietschel ET, Muller-Loennies S. 2000. Structure and activity of endotoxins. In: Aktories K, Just I, editors. Handbook of experimental pharmacology. Berlin: Springer. pp 619-659.
35. Hotokezaka H, Sakai E, Kanaoka K, Saito K, Matsuo K, Kitaura H, Yoshida N, Nakayama K. 2002. U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem 277:47366-47372.
36. Huang M, Wang Y, Collins M, Gu JJ, Mitchell BS, Graves LM. 2002. Inhibition of nucleoside transport by p38 MAPK inhibitors. J Biol Chem 277:28364-28367.
37. Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J, Reddy SV, Hata K, Yamashita K, Hiraga T, Watanabe T, Kukita T, Yoshioka K, Rao A, Yoneda T. 2004. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 114:475-484.
38. Inada K, Endo S, Takahashi K, Suzuki M, Narita T, Yoshida T, Suda H, Komuro T, Yoshida M. 1991. Establishment of a new perchloric acid treatment method to allow determination of the total endotoxin content in human plasma by the limulus test and clinical application. Microbiol Immunol 35:303-314.
39. Kaar SG, Ragab AA, Kaye SJ, Kilic BA, Jinno T, Goldberg VM, Bi Y, Stewart MC, Carter JR, Greenfield EM. 2001. Rapid repair of titanium particle-induced osteolysis is dramatically reduced in aged mice. J Orthop Res 19:171-178.
40. Karaman M, Herrgard S, Treiber D, Gallant P, Atteridge C, Campbell B, Chan K, Ciceri P, Davis M, Edeen P, Faraoni R, Floyd M, Hunt J, Lockhart D, Milanov Z, Morrison M, Pallares G, Patel H, Pritchard S, Wodicka L, Zarrinkar P. 2008. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127-132.
41. Khokhlatchev AV, Canagarajah B, Wilsbacher J, Robinson M, Atkinson M, Goldsmith E, Cobb MH. 1998. Phosphorylation of the MAP kinase promotes its homodimerization and nuclear translocation. Cell 93:605-615.
42. Kim D, Novak M, Wilkins J, Kim M, Sawyer A, Reichert W. 2007. Response of monocytes exposed to phagocytosable particles and discs of comparable surface roughness. Biomaterials 28:4231-4239.
43. Koller M, Hayer S, Redlich K, Ricci R, David JP, Steiner G, Smolen JS, Wagner EF, Schett G. 2005. JNK1 is not essential for TNF-mediated joint disease. Arthritis Res Therapy 7:R166-R173.
44. Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk H, Gaestel M. 1999. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol 1:94-97.
45. Lahti A, Jalonen U, Kankaanranta H, Moilanen E. 2003. c-Jun NH2-terminal kinase inhibitor anthra(1,9-cd)pyrazol-6(2H)-one reduces inducible nitric-oxide synthase expression by destabilizing mRNA in activated macrophages. Mol Pharmacol 64:308-315.
46. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL, Young PR. 1994. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739-745.
47. Lee S, Woo K, Kim S, Kim H, Kwack K, Lee Z, Kim H. 2002. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 30:71-77.
48. Li X, Udagawa N, Itoh K, Suda K, Murase Y, Nishihara T, Suda T, Takahashi N. 2002. p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 143:3105-3113.
49. Li X, Udagawa N, Takami M, Sato N, Kobayashi Y, Takahashi N. 2003. p38 Mitogen-activated protein kinase is crucially involved in osteoclast differentiation but not in cytokine production, phagocytosis, or dendritic cell differentiation of bone marrow macrophages. Endocrinology 144:4999-5005.
50. Lu H, Yang D, Wysk M, Gatti E, Mellman I, Davis R, Flavell R. 1999. Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice. EMBO J 18:1845-1857.
51. Majde JA. 1992. Endotoxin detection. Immunol Today 13:328-329.
52. Mansky KC, Sankar U, Han J, Ostrowski MC. 2002. Microphthalmia transcription factor (MITF) is a target of the p38 MAPK pathway in response to receptor activator of NF-KB ligand signaling. J Biol Chem 277:11077-11083.
53. Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M. 2000. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem 275:31155-31161.
54. Merkel KD, Erdmann JM, McHugh KP, Abu-Amer Y, Ross FP, Teitelbaum SL. 1999. Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am J Pathol 154:203-210.
55. Mody N, Leitch J, Armstrong C, Dixon J, Cohen P. 2001. Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett 502:21-24.
56. Mohit AA, Martin JH, Miller CA. 1995. p493F12 kinase: A novel MAP kinase expressed in a subset of neurons in the human nervous system. Neuron 14:67-78.
57. Montero M, Lobaton CD, Moreno A, Alvarez J. 2002. A novel regulatory mechanism of the mitochondrial Ca2+uniporter revealed by the p38 mitogen-activated protein kinase inhibitor SB202190. FASEB J 16:1955-1957.
58. Morrison DC, Curry BJ. 1979. The use of polymyxin B and C3H/HeJ mouse spleen cells as criteria for endotoxin contamination. J Immunol Methods 27:83-92.
59. Nalepka JL, Greenfield EM. 2004. Detection of bacterial endotoxin in human tissues. Biotechniques 37:413-417.
60. Nelson CL, McLaren AC, McLaren SG, Johnson JJ, Smeltzer MS. 2005. Is aseptic loosening truly aseptic? Clin Orthop 437:25-30.
61. Ojaniemi M, Glumoff V, Harju K, Liljeroos M, Vuori K, Hallman M. 2003. Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages. Eur J Immunol 33:597-605.
62. Overbergh L, Valckx D, Waer M, Mathieu C. 1999. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine 11:305-312.
63. Ragab AA, VanDeMotter R, Lavish SA, Goldberg VM, Ninomiya JT, Carlin CR, Greenfield EM. 1999. Measurement and removal of adherent endotoxin from titanium particles and implant surfaces. J Orthop Res 17:803-809.
64. Rozen S, Skaletsky H. 2000. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132:365-386.
65. Rutault K, Hazzalin CA, Mahadevan LC. 2001. Combinations of ERK and p38 MAPK inhibitors ablate tumor necrosis factor-alpha (TNF-alpha) mRNA induction. Evidence for selective destabilization of TNF-alpha transcripts. J Biol Chem 276:6666-6674.
66. Sabapathy K, Hochedlinger K, Nam SY, Bauer A, Karin M, Wagner EF. 2004. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell 15:713-725.
67. Schrijver IA, Melief MJ, Tak PP, Hazenberg MP, Laman JD. 2000. Antigen-presenting cells containing bacterial peptidoglycan in synovial tissues of rheumatoid arthritis patients coexpress costimulatory molecules and cytokines. Arthritis Rheum 43:2160-2168.
68. Schwarz EM, Lu AP, Goater JJ, Benz EB, Kollias G, Rosier RN, Puzas JE, O'Keefe RJ. 2000. Tumor necrosis factor-alpha/nuclear transcription factor-kappaB signaling in periprosthetic osteolysis. J Orthop Res 18:472-480.
69. Shi L, Kishore R, McMullen MR, Nagy LE. 2002. Lipopolysaccharide stimulation of ERK1/2 increases TNF-alpha production via Egr-1. Am J Physiol Cell Physiol 282:C1205-C1211.
70. Smith M, Lee M, Islam A, Rohrer J, Goldberg V, Beidelschies M, Greenfield E. 2007. The PI3K/Akt pathway mediates the biological response to titanium particles. J Bone Joint Surg 89A:1019-1027.
71. Soloviev A, Schwarz EM, Kuprash DV, Nedospasov SA, Puzas JE, Rosier RN, O'Keefe RJ. 2002. The role of p105 protein in NFkappaB activation in ANA-1 murine macrophages following stimulation with titanium particles. J Orthop Res 20:714-722.
72. Sundfeldt M, Carlsson L, Johansson C, Thomsen P, Gretzer C. 2006. Aseptic loosening, not only a question of wear: A review of different theories. Acta Orthop 77:177-197.
73. Takagi M, Tamaki Y, Hasegawa H, Takakubo Y, Konttinen L, Tiainen V, Lappalainen R, Konttinen Y, Salo J. 2007. Toll-like receptors in the interface membrane around loosening total hip replacement implants. J Biomed Mater Res 81A:1017-1026.
74. Taki N, Tatro JM, Nalepka JL, Togawa D, Goldberg VM, Rimnac CM, Greenfield EM. 2005. Polyethylene and titanium particles induce osteolysis by similar, lymphocyte-independent, mechanisms. J Orthop Res 23:376-383.
75. Taki N, Tatro J, Lowe R, Goldberg V, Greenfield E. 2007. Comparison of the roles of IL-1, IL-6, and TNFa in cell culture and murine models of aseptic loosening. Bone 40:1276-1283.
76. Tatro J, Taki N, Islam A, Goldberg V, Rimnac C, Doerschuk C, Stewart M, Greenfield E. 2007. The balance between endotoxin accumulation and clearance during particle-induced osteolysis in murine calvaria. J Orthop Res 25:361-369.
77. Triantafilou M, Brandenburg K, Kusumoto S, Fukase K, Mackie A, Seydel U, Triantafilou K. 2004. Combinational clustering of receptors following stimulation by bacterial products determines lipopolysaccharide responses. Biochem J 381:527-536.
78. Tunney MM, Patrick S, Curran MD, Ramage G, Hanna D, Nixon JR, Gorman SP, Davis RI, Anderson N. 1999. Detection of prosthetic hip infection at revision arthroplasty by immunofluorescence microscopy and PCR amplification of the bacterial 16S rRNA gene. J Clin Microbiol 37:3281-3290.
79. Tuyt L, Dokter W, Birkenkamp K, Koopmans SB, Lummen C, Kruijer W, Vellenga E. 1999. Extracellular-regulated kinase 1/2, Jun N-terminal kinase, and c-Jun are involved in NF-kappa B-dependent IL-6 expression in human monocytes. J Immunol 162:4893-4902.
80. Vogel S, Hirschfeld MJ, Perera PY. 2001. Signal integration in lipopolysaccharide (LPS)-stimulated murine macrophages. J Endo Res 7:237-241.
81. Wang ZM, Liu C, Dziarski R. 2000. Chemokines are the main proinflammatory mediators in human monocytes activated by Staphylococcus aureus, peptidoglycan, and endotoxin. J Biol Chem 275:20260-20267.
82. Wilkinson JM, Wilson A, Stockley I, Scott I, Macdonald D, Hamer A, Duff G, Eastell R. 2003. Variation in the TNF gene promoter and risk of osteolysis after total hip arthroplasty. J Bone Miner Res 18:1995-2001.
83. Wilkinson JM, Hamer AJ, Stockley I, Eastell R. 2005. Polyethylene wear rate and osteolysis: Critical threshold versus continuous dose-response relationship. J Orthop Res 23:520-525.
84. Wright TM, Goodman SB, 2001. Implant wear in total joint replacement. Rosemount, IL: American Academy of Orthopaedic Surgeons. p. 224.
85. Xing L, Bushnell T, Carlson L, Tai Z, Tondravi M, Siebenlist U, Young F, Boyce B. 2002. NFkappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res 17:1200-1210.
86. Yamanaka Y, Abu-Amer Y, Faccio R, Clohisy J. 2006. Map kinase c-Jun N-terminal kinase mediates PMMA induction of osteoclasts. J Orthop Res 24:1349-1357.
87. Yao J, Mackman N, Edgington TS, Fan ST. 1997. Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. J Biol Chem 272:17795-17801.
88. Zhu W, Downey JS, Gu J, Padova FD, Gram H, Han J. 2000. Regulation of TNF expression by multiple mitogen-activated protein kinase pathways. J Immunol 164:6349-6358.